Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$68.9 million.

  • ImmunityBio's Cash from Operations rose 3023.7% to -$68.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$319.7 million, marking a year-over-year increase of 2411.67%. This contributed to the annual value of -$391.2 million for FY2024, which is 667.44% down from last year.
  • As of Q3 2025, ImmunityBio's Cash from Operations stood at -$68.9 million, which was up 3023.7% from -$79.8 million recorded in Q2 2025.
  • ImmunityBio's 5-year Cash from Operations high stood at -$60.5 million for Q1 2021, and its period low was -$115.3 million during Q4 2023.
  • Its 5-year average for Cash from Operations is -$84.4 million, with a median of -$84.3 million in 2023.
  • Per our database at Business Quant, ImmunityBio's Cash from Operations crashed by 9657.75% in 2021 and then skyrocketed by 3023.7% in 2025.
  • ImmunityBio's Cash from Operations (Quarter) stood at -$71.6 million in 2021, then decreased by 26.64% to -$90.7 million in 2022, then fell by 27.05% to -$115.3 million in 2023, then increased by 26.14% to -$85.1 million in 2024, then rose by 19.08% to -$68.9 million in 2025.
  • Its Cash from Operations stands at -$68.9 million for Q3 2025, versus -$79.8 million for Q2 2025 and -$85.9 million for Q1 2025.